Cover Image
市場調查報告書

放射性醫藥品的全球市場 (2017-2027年):收益預測

The Global Radiopharmaceutical Market Forecast 2017-2027: Revenue Prospects By Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology) Radioisotope, Source (Cyclotrons, Nuclear Reactors), End User and Geography

出版商 Visiongain Ltd 商品編碼 550272
出版日期 內容資訊 英文 234 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
放射性醫藥品的全球市場 (2017-2027年):收益預測 The Global Radiopharmaceutical Market Forecast 2017-2027: Revenue Prospects By Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology) Radioisotope, Source (Cyclotrons, Nuclear Reactors), End User and Geography
出版日期: 2017年07月03日 內容資訊: 英文 234 Pages
簡介

本報告提供全球放射性醫藥品的市場調查,市場定義和概要,市場成長的各種影響因素及市場機會分析,各用途、放射性同位素、來源終端用戶、地區/主要國家趨勢與市場規模的變化與預測,競爭環境,以及主要企業的簡介等彙整。

第1章 報告概要

第2章 市場概要

  • 簡介
  • 市場規模、預測
  • 市場動態
    • 推動因素
    • 阻礙因素
    • 市場機會
    • 市場趨勢
  • 主要法律規章

第3章 市場分析、預測:各用途

  • 簡介
  • 市場規模、預測
    • 癌症
    • 心臟
    • 消化器官
    • 神經內分泌
    • 神經
    • 腎臟
    • 其他
  • 市場魅力目錄

第4章 市場分析、預測:各放射性同位素

  • 簡介
  • 市場規模、預測
    • 鎝99
    • F18
    • 碘131
    • 鎦177
    • 釔90
    • 鎵68
    • 鎵67
    • 銣82
    • 碘123
    • 碘125
    • 銦111
    • 其他
  • 市場魅力目錄

第5章 市場分析、預測:各來源

  • 簡介
  • 市場規模、預測
    • 迴旋加速器
    • 核子反應爐
  • 市場魅力目錄

第6章 市場分析、預測:各終端用戶

  • 簡介
  • 市場規模、預測
    • 醫院
    • 診斷影像中心
    • 門診外科中心
    • 癌症研究機關
  • 市場魅力目錄

第7章 市場分析:各地區

  • 簡介
  • 市場規模、預測
    • 北美
    • 南美
    • 西歐
    • 東歐
    • 亞太地區
    • 中東、非洲
  • 市場魅力目錄

第8章 北美市場分析、預測

第9章 南美市場分析、預測

第10章 西歐市場分析、預測

第11章 東歐市場分析、預測

第12章 亞太地區市場分析、預測

第13章 中東、非洲市場分析、預測

第14章 主要企業

  • 競爭儀表板
  • 企業佔有率分析
  • 企業簡介
    • Siemens AG
    • Eckert & Ziegler
    • Lantheus Medical Imaging, Inc.
    • Cardinal Health, Inc.
    • Bayer AG
    • Bracco Imaging S.P.A
    • Nordion Inc.
    • Advanced Accelerator Applications S.A.
    • Mallinckrodt PLC
  • 其他的企業

第15章 總論

第16章 用語

圖表

目錄
Product Code: PHA0208

Title:
THE GLOBAL RADIOPHARMACEUTICAL MARKET FORECAST 2017-2027
Revenue Prospects by Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others) Radioisotope (Tc-99, F-18, I-131, Lu-177, Y-90, Ga-68, Ga-67, Rb-82, I-123, I-125, I-111, Others), Source (Cyclotrons, Nuclear Reactors), End User (Hospitals, Diagnostic Imaging Centres, Ambulatory Surgical Centres, Cancer Research Institutes) and Geography.

Radiopharmaceuticals - our new study reveals trends, R&D progress, and predicted revenues

Where is the Radiopharmaceutical market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead

Our 234-page report provides 193 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Biosimulation market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, there are forecasts for 6 Applications, 11 Radioisotopes, 2 Sources, and 4 end-users.

Radiopharmaceuticals, by Application

  • Oncology
  • Cardiology
  • Gastroenterology
  • Neuroendocrinology
  • Neurology
  • Nephrology
  • Others

Radiopharmaceuticals, by Radioisotope

  • Tec 99
  • Fluorine 18
  • Iodine131
  • Lutetium 177
  • Yttrium 90
  • Gallium 68
  • Gallium 67
  • Rubidium 82
  • Iodine 123
  • Iodine 125
  • Indium 111
  • Others

Radiopharmaceuticals, by Source

  • Cyclotrons
  • Nuclear Reactors

Radiopharmaceuticals, by End User

  • Hospitals
  • Diagnostic Imaging Centres
  • Ambulatory Surgical Centres
  • Cancer Research Institutes

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 6 regional and 21 leading national markets:

  • North America:
    • The US
    • Canada
  • Latin America:
    • Brazil
    • Mexico
    • Rest of Latin America
  • Western Europe:
    • Germany
    • UK
    • Italy
    • Spain
    • France
    • Nordic Countries
    • Benelux
    • Rest of Western Europe
  • Eastern Europe:
    • Russia
    • Poland
    • Rest of Eastern Europe
  • APAC:
    • Japan
    • China
    • India
    • Australia & New Zealand
    • ASEAN countries
    • Rest of Asia-Pacific
  • MEA:
    • South Africa
    • GCC
    • North African countries
    • Rest of MEA

The report also includes profiles and historical results for some of the leading companies in the radiopharmaceutical market, with a focus on the radiopharmaceutical segment of these companies' operations.

Leading companies and the potential for market growth

Overall world revenue for radiopharmaceutical will surpass $5bn in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing cost of drug development and increasing need for simulation software to reduce

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Biosimulation Market report helps you

In summary, our 234-page report provides you with the following knowledge:

  • Revenue forecasts to 2027 for the Biosimulation market and 4 different segmentations, with forecasts for 6 Applications, 11 Radioisotopes, 2 Sources and 4 End Users - discover the industry's prospects, finding the most lucrative places for investments and revenues
  • Revenue forecasts to 2027 for 21 of the leading national markets - US, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Poland, Russia, Japan, China, India, Australia & New Zealand, ASEAN, GCC, South Africa, Northern African Countries
  • Discussion of what stimulates and restrains companies and the market
  • Prospects for established firms and those seeking to enter the market - including company profiles and forecasts for 9 companies' biosimulation segment revenues to 2027

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the Biosimulation market and leading companies. You will find data, trends and predictions.

Get our report today The Global Radiopharmaceutical Market Forecast 2017-2027: Revenue Prospects by Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others) Radioisotope (Tc-99, F-18, I-131, Lu-177, Y-90, Ga-68, Ga-67, Rb-82, I-123, I-125, I-111, Others), Source (Cyclotrons, Nuclear Reactors), End User (Hospitals, Diagnostic Imaging Centres, Ambulatory Surgical Centres, Cancer Research Institutes) and Geography. Avoid missing out - get our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Introduction
  • 1.2. Why You Should Read This Report
  • 1.3. Key Questions Answered by This Analytical Report
  • 1.4. Who is This Report For?
  • 1.5. Methodology
  • 1.6. Frequently Asked Questions (FAQ)
  • 1.7. Associated Visiongain Reports
  • 1.8. About Visiongain

2. Radiopharmaceutical Market Overview

  • 2.1. Introduction
    • 2.1.1. Market Definition
    • 2.1.2. Market Taxonomy
  • 2.2. Global Radiopharmaceutical Market Size and Forecast
  • 2.3. Market Dynamics
    • 2.3.1. Global Radiopharmaceutical Market: Drivers
      • 2.3.1.1. Evolution towards Centralized Pharmacies
      • 2.3.1.2. Increasing Number of PET and SPECT Scanners Globally
      • 2.3.1.3. Minimizing the Dose in Paediatric Nuclear Imaging
      • 2.3.1.4. Consolidation of Supply Chain
      • 2.3.1.5. Growing Interest of Investors of Conventional Pharmaceutical Industries in the Therapeutic Area
      • 2.3.1.6. Russian Supply Initiative for Mo-99
      • 2.3.1.7. Increasing Domestic Radiopharmaceutical Production
      • 2.3.1.8. Rising Incidence of Cancer and Cardiovascular Diseases
      • 2.3.1.9. Diagnostics Remain a Key Focus of Radiopharmaceuticals Companies
      • 2.3.1.10. Advancement in Radiotracers
    • 2.3.2. Global Radiopharmaceutical Market: Restraints
      • 2.3.2.1. Price Sensitivity and Lack of Specified Guidelines
      • 2.3.2.2. Shorter Half Life of Radiopharmaceuticals Devices
      • 2.3.2.3. Closing of Ageing Research Reactors Worldwide
    • 2.3.3. Global Radiopharmaceutical Market: Opportunity
      • 2.3.3.1. Alternative Diagnostic Radiopharmaceuticals Solutions
      • 2.3.3.2. Lutetium 177
    • 2.3.4. Global Radiopharmaceutical Market: Trends
      • 2.3.4.1. Increasing focus of Manufacturers towards Diagnostic Tracers
      • 2.3.4.2. Increasing Penetration of Radio-therapeutics
      • 2.3.4.3. Fluoro-deoxy glucose (FDG)
      • 2.3.4.4. Gallium-68
      • 2.3.4.5. Nuclear pharmacies
      • 2.3.4.6. Shortage of molybdenum-99/technetium-99m
  • 2.4. Key Regulations

3. Global Radiopharmaceutical Market Analysis and Forecast, By Application

  • 3.1. Introduction
    • 3.1.1. Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Application
  • 3.2. Global Radiopharmaceutical Market Size and Forecast, By Application
    • 3.2.1. Oncology Segment
    • 3.2.2. Cardiology Segment
    • 3.2.3. Gastroenterology
    • 3.2.4. Neuroendocrinology
    • 3.2.5. Neurology
    • 3.2.6. Nephrology
    • 3.2.7. Others
  • 3.3. Global Radiopharmaceutical Market Attractiveness Index, By Application

4. Global Radiopharmaceutical Market Analysis and Forecast, By Radioisotope

  • 4.1. Introduction
    • 4.1.1. Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Radioisotope
  • 4.2. Global Radiopharmaceutical Market Size and Forecast, By Radioisotope
    • 4.2.1. Tec. 99 Segment
    • 4.2.2. F18 Segment
    • 4.2.3. Iodine 131 Segment
    • 4.2.4. Lutetium 177 Segment
    • 4.2.5. Yttrium 90 Segment
    • 4.2.6. Gallium 68 Segment
    • 4.2.7. Gallium 67 Segment
    • 4.2.8. Rubidium 82 Segment
    • 4.2.9. Iodine 123 Segment
    • 4.2.10. Iodine 125 Segment
    • 4.2.11. Indium 111 Segment
    • 4.2.12. Others Segment
  • 4.3. Global Radiopharmaceutical Market Attractiveness Index, By Radioisotope

5. Global Radiopharmaceutical Market Analysis and Forecast, By Source

  • 5.1. Introduction
    • 5.1.1. Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Source
  • 5.2. Global Radiopharmaceutical Market Size and Forecast, By Source
    • 5.2.1. Cyclotrons Segment
    • 5.2.2. Nuclear Reactors Segment
  • 5.3. Global Radiopharmaceutical Market Attractiveness Index, By Source

6. Global Radiopharmaceutical Market Analysis and Forecast, By End User

  • 6.1. Introduction
    • 6.1.1. Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By End User
  • 6.2. Global Radiopharmaceutical Market Size and Forecast, By End User
    • 6.2.1. Hospitals Segment
    • 6.2.2. Diagnostic Imaging Centres Segment
    • 6.2.3. Ambulatory Surgical Centres Segment
    • 6.2.4. Cancer Research Institute Segment
  • 6.3. Global Radiopharmaceutical Market Attractiveness Index, By End User

7. Global Radiopharmaceutical Market Analysis and Forecast, By Region

  • 7.1. Introduction
    • 7.1.1. Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Region
  • 7.2. Global Radiopharmaceutical Market Size and Forecast, By Region
    • 7.2.1. North America
    • 7.2.2. Latin America
    • 7.2.3. Western Europe
    • 7.2.4. Eastern Europe
    • 7.2.5. Asia Pacific
    • 7.2.6. MEA
  • 7.3. Global Radiopharmaceutical Market Attractiveness Index, By Region

8. North America Radiopharmaceutical Market Analysis and Forecast, 2016-2027

  • 8.1. Introduction
    • 8.1.1. North America Radiopharmaceutical Market
    • 8.1.2. North America Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
  • 8.2. North America Radiopharmaceutical Market Size and Forecast, By Country
    • 8.2.1. The U.S. Radiopharmaceutical Market
    • 8.2.2. Canada Radiopharmaceutical Market
  • 8.3. North America Radiopharmaceutical Market Size and Forecast, By Application
  • 8.4. North America Radiopharmaceutical Market Size and Forecast, By Radioisotope
  • 8.5. North America Radiopharmaceutical Market Size and Forecast, By Source
  • 8.6. North America Radiopharmaceutical Market Size and Forecast, By End User
  • 8.7. North America Radiopharmaceutical Market Attractiveness Index
    • 8.7.1. North America Radiopharmaceutical Market Attractiveness Index, By Country
    • 8.7.2. North America Radiopharmaceutical Market Attractiveness Index, By Application
    • 8.7.3. North America Radiopharmaceutical Market Attractiveness Index, By Radioisotope
    • 8.7.4. North America Radiopharmaceutical Market Attractiveness Index, By Source
    • 8.7.5. North America Radiopharmaceutical Market Attractiveness Index, By End User

9. Latin America Radiopharmaceutical Market Analysis and Forecast, 2016-2027

  • 9.1. Introduction
    • 9.1.1. Latin America Radiopharmaceutical Market
    • 9.1.2. Latin America Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
  • 9.2. Latin America Radiopharmaceutical Market Size and Forecast, By Country
    • 9.2.1. Brazil Radiopharmaceutical Market
    • 9.2.2. Mexico Radiopharmaceutical Market
    • 9.2.3. Rest of Latin America Radiopharmaceutical Market
  • 9.3. Latin America Radiopharmaceutical Market Size and Forecast, By Application
  • 9.4. Latin America Radiopharmaceutical Market Size and Forecast, By Radioisotope
  • 9.5. Latin America Radiopharmaceutical Market Size and Forecast, By Source
  • 9.6. Latin America Radiopharmaceutical Market Size and Forecast, By End User
  • 9.7. Latin America Radiopharmaceutical Market Attractiveness Index
    • 9.7.1. Latin America Radiopharmaceutical Market Attractiveness Index, By Country
    • 9.7.2. Latin America Radiopharmaceutical Market Attractiveness Index, By Application
    • 9.7.3. Latin America Radiopharmaceutical Market Attractiveness Index, By Radioisotope
    • 9.7.4. Latin America Radiopharmaceutical Market Attractiveness Index, By Source
    • 9.7.5. Latin America Radiopharmaceutical Market Attractiveness Index, By End User

10. Western Europe Radiopharmaceutical Market Analysis and Forecast, 2017-2027

  • 10.1. Introduction
    • 10.1.1. Western Europe Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
  • 10.2. Western Europe Radiopharmaceutical Market Size and Forecast, By Country
    • 10.2.1. U.K. Radiopharmaceutical Market
    • 10.2.2. France Radiopharmaceutical Market
    • 10.2.3. Germany Radiopharmaceutical Market
    • 10.2.4. Italy Radiopharmaceutical Market
    • 10.2.5. Spain Radiopharmaceutical Market
    • 10.2.6. Nordic Radiopharmaceutical Market
    • 10.2.7. Benelux Radiopharmaceutical Market
    • 10.2.8. Rest of Western Europe Radiopharmaceutical Market
  • 10.3. Western Europe Radiopharmaceutical Market Size and Forecast, By Application
  • 10.4. Western Europe Radiopharmaceutical Market Size and Forecast, By Radioisotope
  • 10.5. Western Europe Radiopharmaceutical Market Size and Forecast, By Source
  • 10.6. Western Europe Radiopharmaceutical Market Size and Forecast, By End User
  • 10.7. Western Europe Radiopharmaceutical Market Attractiveness Index
    • 10.7.1. Western Europe Radiopharmaceutical Market Attractiveness Index, By Country
    • 10.7.2. Western Europe Radiopharmaceutical Market Attractiveness Index, By Application
    • 10.7.3. Western Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope
    • 10.7.4. Western Europe Radiopharmaceutical Market Attractiveness Index, By Source
    • 10.7.5. Western Europe Radiopharmaceutical Market Attractiveness Index, By End User

11. Eastern Europe Radiopharmaceutical Market Analysis and Forecast, 2017-2027

  • 11.1. Introduction
    • 11.1.1. Eastern Europe Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
  • 11.2. Eastern Europe Radiopharmaceutical Market Size and Forecast, By Country
    • 11.2.1. Russia Radiopharmaceutical Market
    • 11.2.2. Poland Radiopharmaceutical Market
    • 11.2.3. Rest of Eastern Europe Radiopharmaceutical Market
  • 11.3. Eastern Europe Radiopharmaceutical Market Size and Forecast, By Application
  • 11.4. Eastern Europe Radiopharmaceutical Market Size and Forecast, By Radioisotope
  • 11.5. Eastern Europe Radiopharmaceutical Market Size and Forecast, By Source
  • 11.6. Eastern Europe Radiopharmaceutical Market Size and Forecast, By End User
  • 11.7. Eastern Europe Radiopharmaceutical Market Attractiveness Index
    • 11.7.1. Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Country
    • 11.7.2. Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Application
    • 11.7.3. Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope
    • 11.7.4. Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Source
    • 11.7.5. Eastern Europe Radiopharmaceutical Market Attractiveness Index, By End User

12. Asia Pacific Radiopharmaceutical Market Analysis and Forecast, 2017-2027

  • 12.1. Introduction
    • 12.1.1. Asia Pacific Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
    • 12.1.2. Asia Pacific Radiopharmaceutical Market, BPS Analysis, By Country
  • 12.2. Asia Pacific Radiopharmaceutical Market Size and Forecast, By Country
    • 12.2.1. China Radiopharmaceutical Market
    • 12.2.2. India Radiopharmaceutical Market
    • 12.2.3. Australia and New Zealand Radiopharmaceutical Market
    • 12.2.4. ASEAN Radiopharmaceutical Market
    • 12.2.5. Japan Radiopharmaceutical Market
    • 12.2.6. Rest of Asia Pacific Radiopharmaceutical Market
  • 12.3. Asia Pacific Radiopharmaceutical Market Size and Forecast, By Application
  • 12.4. Asia Pacific Radiopharmaceutical Market Size and Forecast, By Radioisotope
  • 12.5. Asia Pacific Radiopharmaceutical Market Size and Forecast, By Source
  • 12.6. Asia Pacific Radiopharmaceutical Market Size and Forecast, By End User
  • 12.7. Asia Pacific Radiopharmaceutical Market Attractiveness Index
    • 12.7.1. Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Country
    • 12.7.2. Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Application
    • 12.7.3. Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Radioisotope
    • 12.7.4. Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Source
    • 12.7.5. Asia Pacific Radiopharmaceutical Market Attractiveness Index, By End User

13. MEA Radiopharmaceutical Market Analysis and Forecast, 2017-2027

  • 13.1. Introduction
    • 13.1.1. MEA Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
  • 13.2. MEA Radiopharmaceutical Market Size and Forecast, By Country
    • 13.2.1. GCC Countries Radiopharmaceutical Market
    • 13.2.2. South Africa Radiopharmaceutical Market
    • 13.2.3. North Africa Radiopharmaceutical Market
    • 13.2.4. Rest of MEA Radiopharmaceutical Market
  • 13.3. MEA Radiopharmaceutical Market Size and Forecast, By Application
  • 13.4. MEA Radiopharmaceutical Market Size and Forecast, By Radioisotope
  • 13.5. MEA Radiopharmaceutical Market Size and Forecast, By Source
  • 13.6. MEA Radiopharmaceutical Market Size and Forecast, By End User
  • 13.7. MEA Radiopharmaceutical Market Attractiveness Index
    • 13.7.1. MEA Radiopharmaceutical Market Attractiveness Index, By Country
    • 13.7.2. MEA Radiopharmaceutical Market Attractiveness Index, By Application
    • 13.7.3. MEA Radiopharmaceutical Market Attractiveness Index, By Radioisotope
    • 13.7.4. MEA Radiopharmaceutical Market Attractiveness Index, By Source
    • 13.7.5. MEA Radiopharmaceutical Market Attractiveness Index, By End User

14. Leading Companies in the Radiopharmaceutical Market

  • 14.1. Competition Dashboard
  • 14.2. Company Share Analysis
  • 14.3. Company Profiles
    • 14.3.1. Siemens AG
      • 14.3.1.1. Basic Information
      • 14.3.1.2. Company Overview
      • 14.3.1.3. Product Offering
      • 14.3.1.4. Financial Statements
      • 14.3.1.5. Company Strategy
      • 14.3.1.6. Key Developments
    • 14.3.2. Eckert & Ziegler
      • 14.3.2.1. Basic Information
      • 14.3.2.2. Company Overview
      • 14.3.2.3. Product Offering
      • 14.3.2.4. Financial Statements
      • 14.3.2.5. Key Developments
      • 14.3.2.6. Company Strategy
    • 14.3.3. Lantheus Medical Imaging, Inc.
      • 14.3.3.1. Basic Information
      • 14.3.3.2. Company Overview
      • 14.3.3.3. Product Offering
      • 14.3.3.4. Financial Statements
      • 14.3.3.5. Key Developments
      • 14.3.3.6. Company Strategy
    • 14.3.4. Cardinal Health, Inc.
      • 14.3.4.1. Basic Information
      • 14.3.4.2. Company Overview
      • 14.3.4.3. Product Offering
      • 14.3.4.4. Financial Statements
      • 14.3.4.5. Key Developments
      • 14.3.4.6. Company Strategy
    • 14.3.5. Bayer AG
      • 14.3.5.1. Basic Information
      • 14.3.5.2. Company Overview
      • 14.3.5.3. Product Offering
      • 14.3.5.4. Financial Statements
      • 14.3.5.5. Key Developments
      • 14.3.5.6. Company Strategy
    • 14.3.6. Bracco Imaging S.P.A
      • 14.3.6.1. Basic Information
      • 14.3.6.2. Company Overview
      • 14.3.6.3. Product Offering
      • 14.3.6.4. Key Developments
      • 14.3.6.5. Company Strategy
    • 14.3.7. Nordion Inc.
      • 14.3.7.1. Basic Information
      • 14.3.7.2. Company Overview
      • 14.3.7.3. Product Offering
      • 14.3.7.4. Key Developments
      • 14.3.7.5. Company Strategy
    • 14.3.8. Advanced Accelerator Applications S.A.
      • 14.3.8.1. Basic Information
      • 14.3.8.2. Company Overview
      • 14.3.8.3. Product Offering
      • 14.3.8.4. Financial Statements
      • 14.3.8.5. Key Developments
      • 14.3.8.6. Company Strategy
    • 14.3.9. Mallinckrodt PLC
      • 14.3.9.1. Basic Information
      • 14.3.9.2. Company Overview
      • 14.3.9.3. Product Offering
      • 14.3.9.4. Financial Statements
      • 14.3.9.5. Key Developments
  • 14.4. Other Companies of Interest in the Radiopharmaceutical Market

15. Conclusion

16. Glossary

  • Visiongain Report Sales Order Form
  • Associated Visiongain Reports
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Figures

  • Figure 2.1: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2015-2027
  • Figure 3.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Application Segment, 2015-2027
  • Figure 3.2: Global Radiopharmaceutical Market AGR (%) Comparison, By Application Segment, 2015-2027
  • Figure 3.4: Global Oncology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 3.5: Global Cardiology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 3.6: Global Gastroenterology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Segment, 2014-2027
  • Figure 3.7: Global Neuroendocrinology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 3.8: Global Neurology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 3.9: Global Nephrology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 3.10: Global Other Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 3.11: Global Radiopharmaceutical Market Attractiveness Index, By Application, 2017-2027
  • Figure 4.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Radioisotope Segment, 2015-2027
  • Figure 4.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Tec. 99 Segment, 2014-2027
  • Figure 4.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By F18 Segment, 2014-2027
  • Figure 4.4: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 131 Segment, 2014-2027
  • Figure 4.5: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Lutetium 177 Segment, 2014-2027
  • Figure 4.6: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Yttrium 90 Segment, 2014-2027
  • Figure 4.7: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Gallium 68 Segment, 2014-2027
  • Figure 4.8: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Gallium 67 Segment, 2014-2027
  • Figure 4.9: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Rubidium 82 Segment, 2014-2027
  • Figure 4.10: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 123 Segment, 2014-2027
  • Figure 4.11: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 125 Segment, 2014-2027
  • Figure 4.12: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Indium 111 Segment, 2014-2027
  • Figure 4.13: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Others Segment, 2014-2027
  • Figure 4.14: Global Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017-2027
  • Figure 5.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Source Segment, 2015-2027
  • Figure 5.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Cyclotrons Segment, 2014-2027
  • Figure 5.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Nuclear Reactors Segment, 2014-2027
  • Figure 5.4: Global Radiopharmaceutical Market Attractiveness Index, By Source, 2017-2027
  • Figure 6.1: Global Radiopharmaceutical Market AGR (%) Comparison, By End User Segment, 2015-2027
  • Figure 6.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Hospitals Segment, 2014-2027
  • Figure 6.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Diagnostic Imaging Centres Segment, 2014-2027
  • Figure 6.4: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Ambulatory Surgical Centres Segment, 2014-2027
  • Figure 6.5: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Cancer Research Institute Segment, 2014-2027
  • Figure 6.6: Global Radiopharmaceutical Market Attractiveness Index, By End User, 2017-2027
  • Figure 7.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Region, 2015-2027
  • Figure 7.2: North American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 7.3: Latin American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 7.4: Western European Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 7.5: Eastern European Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 7.6: Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 7.7: MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 7.8: Global Radiopharmaceutical Market Attractiveness Index, By Region, 2017-2027
  • Figure 8.1: North American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 8.2: North American Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015-2027
  • Figure 8.3: US Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 8.4: Canadian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 8.5: North American Radiopharmaceutical Market Attractiveness Index, By Country, 2017-2027
  • Figure 8.6: North American Radiopharmaceutical Market Attractiveness Index, By Application, 2017-2027
  • Figure 8.7: North American Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017-2027
  • Figure 8.8: North American Radiopharmaceutical Market Attractiveness Index, By Source, 2017-2027
  • Figure 8.9: North American Radiopharmaceutical Market Attractiveness Index, By End User, 2017-2027
  • Figure 9.1: Latin America Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 9.2: Latin America Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015-2027
  • Figure 9.3: Brazilian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 9.4: Mexican Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 9.5: Latin America Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Rest of Latin America, 2014-2027
  • Figure 9.6: Latin America Radiopharmaceutical Market Attractiveness Index, By Country, 2017-2027
  • Figure 9.7: Latin America Radiopharmaceutical Market Attractiveness Index, By Application, 2017-2027
  • Figure 9.8: Latin America Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017-2027
  • Figure 9.9: Latin America Radiopharmaceutical Market Attractiveness Index, By Source, 2017-2027
  • Figure 9.10: Latin America Radiopharmaceutical Market Attractiveness Index, By End User, 2017-2027
  • Figure 10.1: Western Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 10.2: Western Europe Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015-2027
  • Figure 10.3: UK Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 10.4: French Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 10.5: German Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 10.6: Italian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 10.7: Spanish Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 10.8: Nordic Radiopharmaceutical Market Value (US$m) Forecast and AGR (%),2014-2027
  • Figure 10.9: Benelux Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 10.10: Rest of Western Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 10.11: Western Europe Radiopharmaceutical Market Attractiveness Index, By Country, 2017-2027
  • Figure 10.12: Western Europe Radiopharmaceutical Market Attractiveness Index, By Application, 2017-2027
  • Figure 10.13: Western Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017-2027
  • Figure 10.14: Western Europe Radiopharmaceutical Market Attractiveness Index, By Source, 2017-2027
  • Figure 10.15: Western Europe Radiopharmaceutical Market Attractiveness Index, By End User, 2017-2027
  • Figure 11.1: Eastern Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 11.2: Eastern Europe Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015-2027
  • Figure 11.3: Russian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 11.4: Polish Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 11.5: Rest of Eastern Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 11.6: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Country, 2017-2027
  • Figure 11.7: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Application, 2017-2027
  • Figure 11.8: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017-2027
  • Figure 11.9: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Source, 2017-2027
  • Figure 11.10: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By End User, 2017-2027
  • Figure 12.1: Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 12.2: Asia Pacific Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015-2027
  • Figure 12.3: Chinese Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 12.4: Indian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 12.5: Australia and New Zealand Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 12.6: ASEAN Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 12.7: Japanese Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 12.8: Rest of Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 12.9: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Country, 2017-2027
  • Figure 12.10: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Application, 2017-2027
  • Figure 12.11: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017-2027
  • Figure 12.12: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Source, 2017-2027
  • Figure 12.13: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By End User, 2017-2027
  • Figure 13.1: MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 13.2: MEA Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015-2027
  • Figure 13.3: MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By GCC Countries, 2014-2027
  • Figure 13.4: South African Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 13.5: North African Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 13.6: Rest of MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014-2027
  • Figure 13.7: MEA Radiopharmaceutical Market Attractiveness Index, By Country, 2017-2027
  • Figure 13.8: MEA Radiopharmaceutical Market Attractiveness Index, By Application, 2017-2027
  • Figure 13.9: MEA Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017-2027
  • Figure 13.10: MEA Radiopharmaceutical Market Attractiveness Index, By Source, 2017-2027
  • Figure 13.11: MEA Radiopharmaceutical Market Attractiveness Index, By End User, 2017-2027
  • Figure 14.1: Leading Radiopharmaceutical Companies, By Market Share (%), 2016
  • Figure 14.2: Siemens Segment Percentage Split (2016)
  • Figure 14.3: Siemens Geographical Percentage Split (2016)
  • Figure 14.4: Eckert & Ziegler Segment Percentage Split
  • Figure 14.5: Eckert & Ziegler Geographic Percentage Split
  • Figure 14.6: Lantheus Medical Imaging, Inc. Segment Percentage Split
  • Figure 14.7: Lantheus Medical Imaging, Inc. Geographical Percentage Split
  • Figure 14.8: Cardinal Health, Inc. Segment Percentage Split
  • Figure 14.9: Cardinal Health, Inc. Geographical Percentage Split
  • Figure 14.10: Bayer AG Segment Percentage Split
  • Figure 14.11: Bayer AG Segment Geographical Percentage Split
  • Figure 14.12: Advanced Accelerator Applications S.A., Segment Percentage Split
  • Figure 14.13: Advanced Accelerator Applications S.A., Geographical Percentage Split
  • Figure 14.14: Mallinckrodt PLC Segment Percentage Split
  • Figure 14.15: Mallinckrodt PLC Geographical Percentage Split
  • Figure 15.1: Radiopharmaceutical Market Drivers and Restraints

List of Tables

  • Table 2.1: Global Radiopharmaceutical Market Segmentation
  • Table 3.1: Global Radiopharmaceutical Market Value (US$m) Forecast, By Radioisotope, 2016-2027
  • Table 3.2: Global Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
  • Table 4.1: Global Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
  • Table 4.1: Global Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
  • Table 5.1: Global Radiopharmaceutical Market Value (US$m) Forecast, By Radioisotope, 2016-2027
  • Table 6.1: Global Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
  • Table 7.1: Global Radiopharmaceutical Market Forecast, By Region ($m, AGR%, CAGR%) 2016-2027
  • Table 8.1: North American Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
  • Table 8.2: North American Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
  • Table 8.2: North American Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
  • Table 8.3: North American Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
  • Table 8.4: North American Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
  • Table 9.1: Latin America Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
  • Table 9.2: Latin America Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
  • Table 9.3: Latin America Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
  • Table 9.3: Latin America Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
  • Table 9.4: Latin America Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
  • Table 9.5: Latin America Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2017
  • Table 10.1: Western Europe Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
  • Table 10.2: Western Europe Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
  • Table 10.3: Western Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
  • Table 10.3: Western Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
  • Table 10.4: Western Europe Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
  • Table 10.5: Western Europe Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
  • Table 11.1: Eastern Europe Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
  • Table 11.2: Eastern Europe Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
  • Table 11.3: Eastern Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
  • Table 11.3: Eastern Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
  • Table 11.4: Eastern Europe Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
  • Table 11.5: Eastern Europe Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
  • Table 12.1: Asia Pacific Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
  • Table 12.2: Asia Pacific Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
  • Table 12.3: Asia Pacific Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
  • Table 12.3: Asia Pacific Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
  • Table 12.4: Asia Pacific Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
  • Table 12.5: Asia Pacific Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
  • Table 13.1: MEA Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
  • Table 13.2: MEA Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
  • Table 13.3: MEA Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
  • Table 13.3: MEA Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
  • Table 13.4: MEA Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
  • Table 13.5: MEA Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
  • Table 14.1: Radiopharmaceutical Market Competitive Overview
  • Table 14.2: Siemens AG Overview, 2016
  • Table 14.3: Siemens AG Financial Overview, 2014-2016
  • Table 14.4: Siemens Recent Developments
  • Table 14.5: Eckert & Ziegler Overview, 2016
  • Table 14.7: Eckert & Ziegler Recent Developments
  • Table 14.8: Lantheus Medical Imaging, Inc., Overview, 2016
  • Table 14.9: Lantheus Medical Imaging, Inc., Financial Overview 2013-2015
  • Table 14.10: Lantheus Medical Imaging, Inc., Recent Developments
  • Table 14.13: Cardinal Health Inc. Recent Developments
  • Table 14.14: Bayer AG, Overview, 2016
  • Table 14.15: Bayer AG, Financial Overview, 2014-2016
  • Table 14.16: Bayer AG Recent Developments
  • Table 14.17: Bracco Imaging S.P.A, Overview, 2016
  • Table 14.18: Bracco Imaging S.P.A, Recent Developments
  • Table 14.19: Nordion Inc., Overview, 2016
  • Table 14.20: Siemens Recent Developments
  • Table 14.21: Advanced Accelerator Applications S.A., Overview, 2016
  • Table 14.22: Advanced Accelerator Applications S.A., Financial Overview, 2013-2015
  • Table 14.23: Advanced Accelerator Applications S.A. Recent Developments
  • Table 14.24: Mallinckrodt PLC, Overview, 2016
  • Table 14.25: Mallinckrodt PLC, Overview, 2016
  • Table 14.26: Siemens Recent Developments
  • Table 14.27: Other Companies of Interest in the Radiopharmaceutical Market

Companies Listed:

  • ABX GmbH
  • Actinium Pharmaceuticals, Inc.
  • Advanced accelerator applications S.A
  • Advion, Inc.
  • Alliance Medical
  • ANMI
  • Avid Radiopharmaceuticals
  • Bayer
  • Biodex
  • Biomedica Life Sciences S.A
  • Bracco Imaging S.P.A
  • BV Cyclotron VU
  • Cardinal Health, Inc.
  • Clarity Pharmaceuticals
  • Comecer Group
  • Coquí RadioPharmaceuticals, Corp.
  • Coquí RadioPharmaceuticals, Corp.
  • Cyclomedical
  • Cyclopharm
  • Danish International
  • DuChemBio Co., Ltd
  • Eckert & Ziegler
  • Eczacibasi-Monrol Nuclear Products
  • Eli Lilly and Company
  • ELYSIA s.a.
  • Euromechanics saveRay GmbH
  • FUJIFILM Holdings Corporation
  • GIPHARMA
  • IDB Holland BV
  • Immunomedics, Inc.
  • Ion Beam Applications
  • IQ Medical Services
  • Isologic Innovative Radiopharmaceuticals
  • Isorad Ltd
  • IsoTherapeutics Group, LLC
  • Jubilant Pharma. LLC
  • Lantheus Medical Imaging, Inc.
  • M.G.P.
  • M.G.P. spol. s r. o.
  • Medi-Radiopharma
  • Modus Medical Devices Inc.
  • MR Solutions
  • Navidea Biopharmaceuticals, Inc.
  • Nordion, Inc
  • OctreoPharm Sciences GmbH
  • Optimized Radiochemical Applications
  • PARS ISOTOPE Co.
  • PET Pharm Biotech Co., Ltd
  • Piramal Group
  • Rapidscan Pharma Solutions
  • ROTOP Pharmaka GmbH
  • RPH Group
  • SANLAR Group
  • SCETI K.K
  • Shertech Pharmacy
  • Siemens AG
  • Siemens Healthineers
  • Sirtex Medical Europe GmbH
  • SK CAPITAL
  • St Mary's Pharmaceutical
  • Synektik Group
  • Tema Sinergie
  • The Voxel S.A.
  • Toshiba Medical Systems Corporation
  • Tracer Pharma ApS
  • TRASIS S.A.
  • Triad Isotopes, Inc.
  • Zevacor Molecular
  • Zevacor Pharma, Inc.

List of Organizations:

  • European Medicines Agency
  • Food and Drug Administration (FDA)
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Ministry of Health, Labor, and Welfare (MHLW)
  • National Health Service (UK)
  • National Institutes of Health (NIH)
  • Organization for Economic Co-operation and Development (OECD)
  • World Health Organization (WHO)
Back to Top